Conditioning regimen dosing calculation for patients with obesity undergoing hematopoietic stem cell transplantation

Jitnarin N, Kosulwat V, Rojroongwasinkul N, Boonpraderm A, Haddock CK, Poston WS. Prevalence of overweight and obesity in Thai population: results of the National Thai Food Consumption Survey. Eat Weight Disord. 2011;1:e242-9.

Sakboonyarat B, Pornpongsawad C, Sangkool T, Phanmanas C, Kesonphaet N, Tangthongtawi N, et al. Trends, prevalence and associated factors of obesity among adults in a rural community in Thailand: serial cross-sectional surveys, 2012 and 2018. BMC Public Health. 2020;20:850.

Lyman GH, Sparreboom A. Chemotherapy dosing in overweight and obese patients with cancer. Nat Rev Clin Oncol. 2013;10:451-9.

American Society for Blood and Marrow Transplantation practice guideline committee. Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee. Biol Blood Marrow Transplant. 2014;20:600-16.

Horowitz NS, Wright AA. Impact of obesity on chemotherapy management and outcomes in women with gynecologic malignancies. Gynecol Oncol. 2015;138:201-6.

Langebrake C. Overweight and Obese Patients. In: Carreras E, Dufour C, Mohty M, Kröger N, editors. The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. Cham (CH): Springer Copyright 2019, EBMT and the Author(s). 2019. p. 493-8.

Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D. Million Women Study Collaboration Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ (Clinical research ed). 2007;335:1134.

Hoffman R, Benz EJ, Silberstein LE, Heslop HE, Jeffrey I, Weitz JI, et al. Hematology, Basic and Practie 7th edition. 7 ed. Hoffman R, editor. Philadelphia: Elsevier; 2018.

Goldie JH, Coldman AJ. The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Cancer Res. 1984;44:3643-53.

Bosly A, Bron D, Van Hoof A, De Bock R, Berneman Z, Ferrant A, et al. Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Ann Hematol. 2008;87:277-83.

Kwak LW, Halpern J, Olshen RA, Horning SJ. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol. 1990;8:963-77.

Pettengell R, Schwenkglenks M, Bosly A. Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy. Ann Hematol. 2008;87:429-30.

Gyurkocza B, Sandmaier BM. Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. Blood 2014;124:344-53.

Griggs JJ, Sorbero ME, Lyman GH. Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med. 2005;165:1267-73.

Rosner GL, Hargis JB, Hollis DR, Budman DR, Weiss RB, Henderson IC, et al. Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541. J Clin Oncol. 1996;14:3000-8.

Shem-Tov N, Labopin M, Moukhtari L, Ciceri F, Esteve J, Giebel S, et al. Chemotherapy dose adjustment for obese patients undergoing hematopoietic stem cell transplantation: a survey on behalf of the Acute Leukemia Working Party of the European Society

for Blood and Marrow Transplantation. Oncologist. 2015;20:50-5.

Griggs JJ, Mangu PB, Temin S, Lyman GH. Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Oncology Practice. 2012;8:e59-e61.

Griggs JJ, Bohlke K, Balaban EP, Dignam JJ, Hall ET, Harvey RD, et al. Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update. Journal of Clinical Oncology. 2021;39:2037-48.

Griffin SP, Wheeler SE, Wiggins LE, Murthy HS, Hsu JW, Richards AI. Pharmacokinetic and clinical outcomes when ideal body weight is used to dose busulfan in obese hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2019;54:218-25.

Casas A, Torroba B, Tapia B, Garcia-Del-Barrio MA. 4CPS-114 Dosing of platinum and taxanes in obese patients: a systematic review. European Journal of Hospital Pharmacy. 2019;26:A121.

Cuesta CG, Jornet JEP, Blesa JMG, Perez AV, Hueso FJC, Royo LM. Toxicity and effectiveness of carboplatin in obese or overweight patients. Journal of Oncology Pharmacy Practice. 2018;25:1328-35.

Fair C, Shanley R, Rogosheske J, Lazaryan A, McClune B, Brunstein CG, et al. BEAM conditioning is well-tolerated and yields similar survival in obese and non-obese patients with lymphoma: no requirement for weight-based dose modifications. Bone marrow transplantation. 2017;52:491-3.

Bachanova V, Rogosheske J, Shanley R, Burns LJ, Smith SM, Weisdorf DJ, et al. Adjusting Cyclophosphamide Dose in Obese Patients with Lymphoma Is Safe and Yields Favorable Outcomes after Autologous Hematopoietic Cell Transplantation. Biology of blood and marrow transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2016;22:571-4.

Percival MEM, Medeiros BC. Chemotherapy dose in obese AML patients: to cap or not to cap? Leuk Res. 2015;39:30-2.

Fields SZ, Budman DR, Young RR, Kreis W, Ingram R, Schulman P, et al. Phase I study of high-dose etoposide phosphate in man. Bone Marrow Transplant. 1996;18:851-6.

Grazziutti ML, Dong L, Miceli MH, Krishna SG, Kiwan E, Syed N, et al. Oral mucositis in myeloma patients undergoing melphalan based autologous stem cell transplantation: incidence, risk factors and a severity predictive model. Bone Marrow Transplant. 2006;38:501-6.

Brunstein CG, Pasquini MC, Kim S, Fei M, Adekola K, Ahmed I, et al. Effect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Hematopoietic Cell Transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2019;25:480-7.